Email Address
Please enter your official email address
We notice that your permissions preference cookie is missing. Please enter your email address so we can determine if you need to complete a permission form or verify that you have already completed this form. Receiving permission from our users is an important part of our compliance with international privacy regulations. Your email address will not be shared without your permission. Please refer to our
privacy policy
for information on how we protect your personal information.
Welcome to AdisInsight
We need some information from you before you start using the platform.
This information will allow us to better understand how AdisInsight is being used.
It does not require or replace the individual login accounts that many of you use to save searches and create email alerts.
Protecting your personal information is important.
That is why AdisInsight collects the minimum amount of information necessary to enable functionality, report usage, and contact you with information about AdisInsight.
For further information on how we protect and process your personal information, please refer to our
privacy policy.
Terms of Service
By accessing or using the AdisInsight platform you agree to the terms of use.
Please select terms of use
How much you and your colleagues use AdisInsight often determines if your organization will continue paying to provide access to the platform.
The number of times you access AdisInsight, the number of searches you performed, and the number of profiles you viewed will be provided to your organization both in aggregate with other users and individually by your email address.
You have the right to opt-out of sharing your email address with your organization but doing so may negatively affect your organization’s decision to renew their subscription to AdisInsight. If you opt-out your email will still be collected for registration purposes.
Please choose your email permissions
Get more from AdisInsight
Keep up to date with all things AdisInsight by signing up to receive our product bulletin, which includes related content from Springer Nature such as white papers, product news, industry commentaries, and webinar invites, straight to your inbox. Unsubscription is always possible via email.
Alternative Names:
Anti-PD-L1/TGFbetaRII-fusion-protein; Anti-PDL1/TGFb Trap MSB0011359C; GSK-4045154; M-7824; MSB-0011359C
Latest Information Update: 14 Jan 2023
Price :
$50
*
Adis is an information provider.
We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.
At a glance
Originator
EMD Serono; Merck KGaA
Developer
Bergonie Institute; EMD Serono; EMD Serono Research & Development Institute; GlaxoSmithKline; M. D. Anderson Cancer Center; Merck KGaA; National Cancer Institute (USA); Precigen Inc; University of Hong Kong
Class
Antineoplastics; Immunotherapies; Recombinant fusion proteins
Phase I/II
Brain metastases; Colorectal cancer; Pancreatic cancer; Small cell lung cancer
Phase I
Urogenital cancer
No development reported
HER2 negative breast cancer
Most Recent Events
10 Nov 2022
Merck Biopharma completes a phase-II/III clinical trial in Biliary cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA, Argentina, Australia, Brazil, Chile, China, France, Germany, Italy, Japan, South Korea, Poland, Spain, Taiwan, UK (NCT04066491) (JapicCTI194961)
30 Sep 2022
Merck KGaA and EMD Serono completes a phase II trial in Biliary tract cancer (Late-stage disease; Metastatic disease; Monotherapy; Second-line therapy or greater) in USA, China, France, Italy, Japan, Spain, South Korea, Taiwan and the UK (IV) (NCT03833661) (EudraCT2018-003707-19)
09 Sep 2022
Initial adverse events, efficacy and pharmacokinetics data from a phase I trial in Solid tumours presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)
Subscriber content
You need to be a logged in subscriber to view this content.
If your organization
has a subscription
then there are several options available to help you access AdisInsight, even while working remotely.
IP authentication when working within your organization’s network.
Login
with a username/password associated to your organization’s account.
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Federated access using single sign-on credentials.
If your organization
does not have a subscription
to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.
Contact your organization’s admin about adding this content to your AdisInsight subscription
